Ipsen (Group)

https://www.ipsen.com

Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.4 billion in 2015. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its fields of expertise cover oncology, neurosciences and endocrinology (adult & pediatric). Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer and neuro-endocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford, UK; Cambridge, US). In 2015, R&D expenditure totaled close to €193 million. The Group has more than 4,600 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. *

	Start	2007-08-25 existent
	Industry	pharmaceutical
	Person	Meek, David (Ferring 202001– CEO of FerGene before Ipsen + Baxalta + Endocyte + Novartis + JnJ)
	Person 2	le Chatelier, Aymeric (Ipsen 201603 CFO)

	Region	Paris
	Country	France
	Street	42 rue du Docteur Blanche
	City	75016 Paris
	Tel	+33-1-443043-43
		Address record changed: 2020-12-02

Basic data	Employees	F: 1,001 to 5,000 (2017-02-23)
	Currency	EUR
	Annual sales	1,671,100,000 (revenues, consolidated (2016) 2016-12-31)
	Profit	226,600,000 (2016-12-31)
	Cash	425,500,000 (2016-12-31)

		* Document for ï¿½About Sectionï¿½:

		Record changed: 2021-04-05